Remix''s therapeutic approach led to the discovery of REM-422, an investigational small molecule designed to modulate RNA processing in oncology, currently being evaluated in two clinical programs, 1) the ARIA clinical study, a Phase 1/2 clinical study in adenoid cystic carcinoma (ACC), and 2) a Phase 1 clinical study in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS). Working closely with Commercial, Medical Affairs, Clinical Development, Regulatory, Market Access, Technical Operations, Quality, Finance, Legal and Compliance, IT, and Human Resources, this individual will connect workstreams, surface risks, and help leadership make timely decisions.